Altur S.A. (BVB:ALT)
0.0805
0.00 (0.00%)
At close: Jul 31, 2025
Theseus Pharmaceuticals Balance Sheet
Financials in millions RON. Fiscal year is January - December.
Millions RON. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Cash & Equivalents | 0.57 | 2.42 | 3.95 | 0.06 | 0.09 | 1.67 | Upgrade |
Cash & Short-Term Investments | 0.57 | 2.42 | 3.95 | 0.06 | 0.09 | 1.67 | Upgrade |
Cash Growth | -63.62% | -38.76% | 6687.82% | -36.58% | -94.49% | 724.98% | Upgrade |
Accounts Receivable | 21.45 | 15.51 | 15.51 | 16.19 | 12.99 | 13.37 | Upgrade |
Other Receivables | 7.14 | 6.13 | 7.44 | 6.51 | 6.17 | 13.77 | Upgrade |
Receivables | 28.59 | 21.63 | 22.96 | 22.71 | 19.16 | 27.14 | Upgrade |
Inventory | 22.98 | 21.77 | 27.29 | 25.08 | 16.79 | 14.99 | Upgrade |
Prepaid Expenses | 0.65 | 0.02 | - | - | - | - | Upgrade |
Other Current Assets | - | - | - | 0.11 | 0.06 | 0.35 | Upgrade |
Total Current Assets | 52.8 | 45.85 | 54.2 | 47.95 | 36.1 | 44.15 | Upgrade |
Property, Plant & Equipment | 55.48 | 56.68 | 60.27 | 63.97 | 69.64 | 46.72 | Upgrade |
Long-Term Investments | - | - | - | - | - | 0.01 | Upgrade |
Other Intangible Assets | - | - | - | 0.03 | 0.07 | 0.04 | Upgrade |
Other Long-Term Assets | - | - | 0.17 | 0.34 | 0.07 | 0.06 | Upgrade |
Total Assets | 109.02 | 103.26 | 115.37 | 112.29 | 105.88 | 90.98 | Upgrade |
Accounts Payable | 17.5 | 11.7 | 22.76 | 16.21 | 20.53 | 15.56 | Upgrade |
Accrued Expenses | - | - | - | 1.73 | 2.49 | 14.72 | Upgrade |
Current Portion of Long-Term Debt | 13.07 | 10.21 | 16.29 | 20.01 | 21.58 | 18.71 | Upgrade |
Current Portion of Leases | - | - | - | - | 0.6 | 0.56 | Upgrade |
Current Unearned Revenue | - | - | - | - | 1.33 | 0.52 | Upgrade |
Other Current Liabilities | - | - | - | 7.95 | 4.3 | - | Upgrade |
Total Current Liabilities | 30.61 | 21.91 | 39.05 | 45.89 | 50.83 | 50.07 | Upgrade |
Long-Term Debt | 9.26 | 11.88 | 11.98 | 0.82 | 0.61 | 3.03 | Upgrade |
Long-Term Leases | - | 0.33 | 0 | - | 1.45 | 1.88 | Upgrade |
Long-Term Unearned Revenue | 4.96 | 4.96 | - | 10.22 | 0.4 | 1.11 | Upgrade |
Long-Term Deferred Tax Liabilities | 0.95 | 0.95 | 1.04 | 1.09 | 1.15 | 3.2 | Upgrade |
Other Long-Term Liabilities | 0.46 | 0.46 | 0.91 | 0.96 | 0.8 | 1.09 | Upgrade |
Total Liabilities | 46.24 | 40.51 | 52.99 | 59 | 55.24 | 60.38 | Upgrade |
Common Stock | 30.6 | 30.6 | 30.6 | 30.6 | 82.43 | 82.43 | Upgrade |
Retained Earnings | -11.87 | -11.9 | -12.26 | -21.59 | -76.08 | -270.25 | Upgrade |
Comprehensive Income & Other | 44.04 | 44.04 | 44.04 | 44.28 | 44.28 | 218.42 | Upgrade |
Shareholders' Equity | 62.77 | 62.75 | 62.39 | 53.29 | 50.64 | 30.6 | Upgrade |
Total Liabilities & Equity | 109.02 | 103.26 | 115.37 | 112.29 | 105.88 | 90.98 | Upgrade |
Total Debt | 22.34 | 22.43 | 28.27 | 20.83 | 24.23 | 24.17 | Upgrade |
Net Cash (Debt) | -21.76 | -20.01 | -24.32 | -20.77 | -24.14 | -22.5 | Upgrade |
Net Cash Per Share | -0.07 | -0.07 | -0.08 | -0.07 | -0.03 | -0.03 | Upgrade |
Filing Date Shares Outstanding | 306.05 | 306.05 | 306.05 | 306.05 | 824.39 | 824.39 | Upgrade |
Total Common Shares Outstanding | 306.05 | 306.05 | 306.05 | 306.05 | 824.39 | 824.39 | Upgrade |
Working Capital | 22.2 | 23.93 | 15.15 | 2.06 | -14.74 | -5.92 | Upgrade |
Book Value Per Share | 0.21 | 0.21 | 0.20 | 0.17 | 0.06 | 0.04 | Upgrade |
Tangible Book Value | 62.77 | 62.75 | 62.39 | 53.26 | 50.57 | 30.56 | Upgrade |
Tangible Book Value Per Share | 0.21 | 0.21 | 0.20 | 0.17 | 0.06 | 0.04 | Upgrade |
Land | 20.93 | 20.93 | 20.93 | 20.93 | 20.93 | 7.24 | Upgrade |
Buildings | 27.08 | 26.84 | 25.58 | 25.1 | 25.54 | 21.58 | Upgrade |
Machinery | 92.53 | 93.04 | 98.05 | 97.87 | 95.93 | 95.96 | Upgrade |
Construction In Progress | - | 1.89 | 1.58 | - | 0.44 | 0.47 | Upgrade |
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.